Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …

Patients with pancreatic cancer normally present with advanced disease that is lethal and
notoriously difficult to treat. However, clinical developments over the past decade have been …

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death in
the Western world. Owing to a lack of specific symptoms and no accessible precursor …

Molecular targeted therapy is widely utilized and effective in a number of solid tumors. In
pancreatic adenocarcinoma, targeted therapy has been extensively evaluated; however …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-
year survival rate of approximately 5%. Several target agents have been tested in PDAC, but …

Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early
locoregional spread and distant metastases at diagnosis, leading to dismal prognosis and …

The prognosis of patients with pancreatic cancer is extremely poor, and current systemic
therapies provide marginal survival benefits for treated patients. The era of targeted …

Pancreatic ductal adenocarcinoma (PDAC) is an incurable lethal disease whose incidence
rate is growing. There is no effective screening for detection of early stage tumors and, in …

Pancreatic adenocarcinoma ranks as the most challenging of human malignancies, with
overall 5-year survivorship being measured in a couple of percent. Major progress has …

Pancreatic cancer is the fourth leading cause of cancer death in the US and is expected to
become the second leading cause of cancer-related deaths in the next decade. Despite 5 …